title: [Evaluation of the effect of living donor liver transplantation on the treatment of severe hepatitis].
abstract: OBJECTIVE
  To evaluate the effect of living donor liver transplantation on the treatment of severe hepatitis.
  
  
  METHODS
  18 patients with severe hepatitis received liver transplantation (transplanted severe hepatitis group), 28 patients with sever hepatitis received non surgical treatment (non-transplanted severe hepatitis group), and 30 patients with end stage liver cirrhosis (without cancer) received liver transplantation (transplanted cirrhosis group). The vital sign, blood coagulation, and renal function were monitored during operation. After liver transplantation, patients received immunosuppressive therapy (including tacrolimus or cyclosporine A, mycophenolate, mofetil and corticosteroids), intensive care, antiviral therapy (including lamivudine and HBIg) and other treatments (including restoration of liver function and prevention of blood coagulation). Pre-operation data, operation procedure, liver function, renal function and the operation complications of three groups were compared, and survival rate at 1, 6 and 12 months after operation was followed.
  
  
  RESULTS
  There was no significant difference in the operation time, warm ischemia time, hypothermic ischemia time and Graft-to-recipient weight ratio between the two transplantation groups. The blood loss volume and blood transfusion volume in the transplanted severe hepatitis group were higher than that those in the cirrhosis transplantation group (t = 0.001, 0.004). The levels of TBil, ALT and AST at day 7 after operation were (100.5 +/- 96.4)mumol/L, (215.3 +/- 195.7) U/L , (209.8 +/- 188.6) U/L in the transplanted severe hepatitis group, and (53.3 +/- 31.9)mumol/L, (56.3 +/- 22.1) U/L, (51.3 +/- 13.5) U/L in the transplanted cirrhosis group (t = 0.017, 0.021, 0.004). However, there was no significant difference in the levels of Alb and Cr between these two groups (P > 0.05). Survival rate was 88.89%, 83.33% 83.33% in the transplanted severe hepatitis group, and 96.67%, 93.33% 93.33% in the transplanted cirrhosis group at 1, 6 and 12 months after transplantation.
  
  
  CONCLUSIONS
  Living donor liver transplantation is one of effect ways for the treatment of severe hepatitis.
authors.affiliation: Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Guo
authors.initials: G
authors.lastname: Li
authors.forename: Tian-Fu
authors.initials: TF
authors.lastname: Wen
authors.forename: Lü-Nan
authors.initials: LN
authors.lastname: Yan
authors.forename: Zhe-Yu
authors.initials: ZY
authors.lastname: Chen
authors.forename: Yong
authors.initials: Y
authors.lastname: Zeng
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Ji-Chun
authors.initials: JC
authors.lastname: Zhao
authors.forename: Wen-Tao
authors.initials: WT
authors.lastname: Wang
authors.forename: Jia-Yin
authors.initials: JY
authors.lastname: Yang
authors.forename: Ming-Qing
authors.initials: MQ
authors.lastname: Xu
authors.forename: Yu-Kui
authors.initials: YK
authors.lastname: Ma
authors.forename: Hong
authors.initials: H
authors.lastname: Wu